Jhony De La Cruz Vargas

Prof. Dr. Jhony De La Cruz Vargas

orcid

Research Focus & Metrics

Academic Career Length

59Years (1968-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ACAlfredo Carrato
Alfredo Carrato
ASAnna Swieboda-Sadlej
Anna Swieboda-Sadlej
MSMarzanna Staszewska-Skurczynska
Marzanna Staszewska-Skurczynska
RLRobert Lim
Robert Lim
LRLaslo Roman
Laslo Roman
ECEric Van Cutsem
Eric Van Cutsem
Purpose: This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC). Patients and Methods: Patients were randomly assigned to receive FOLFIRI and either sunitinib (37.5 mg per day) or placebo (4 weeks on treatment, followed by 2 weeks off [schedule 4/2]) until disease progression. The primary end point was progression-free survival (PFS). Secondary end points included overall survival, safety, and patient-reported outcomes. The correlation between genotype and clinical outcomes was also analyzed. Results: In all, 768 patients were randomly assigned to sunitinib plus FOLFIRI (n = 386) or placebo plus FOLFIRI (n = 382). Following a second prespecified interim analysis, the study was stopped because of potential futility of sunitinib plus FOLFIRI. Final results are reported. The PFS hazard ratio was 1.095 (95% CI, 0.892 to 1.344; one-sided stratified log-rank P = .807), indicating a lack of superiority for sunitinib plus FOLFIRI. Median PFS for the sunitinib arm was 7.8 months (95% CI, 7.1 to 8.4 months) versus 8.4 months (95% CI, 7.6 to 9.2 months) for the placebo arm. Sunitinib plus FOLFIRI was associated with more grade ≥ 3 adverse events and laboratory abnormalities than placebo (especially diarrhea, stomatitis/oral syndromes, fatigue, hand-foot syndrome, neutropenia, thrombocytopenia, anemia, and febrile neutropenia). More deaths as a result of toxicity (12 v four) and significantly more dose delays, dose reductions, and treatment discontinuations occurred in the sunitinib arm. Conclusion: Sunitinib 37.5 mg per day (schedule 4/2) plus FOLFIRI is not superior to FOLFIRI alone and has a poorer safety profile. This combination regimen is not recommended for previously untreated mCRC.

1 December 2013 in Clinical Breast Cancer
Verified
Journal Article
Closed access
SRSocorro Romero-Figueroa
Socorro Romero-Figueroa
JGJosé de Jesús Garduño-García
José de Jesús Garduño-García
JDJesús Duarte-Mote
Jesús Duarte-Mote
GMGuadalupe Matute-González
Guadalupe Matute-González
AGAngel Gómez-Villanueva
Angel Gómez-Villanueva
Jhony De La Cruz VargasJhony De La Cruz Vargas
Jhony De La Cruz Vargas

27 August 2022 in Drones
Verified
Journal Article
Open access
PDF file
Alejandro Valencia-AriasAlejandro Valencia-Arias
Alejandro Valencia-Arias
Paula Andrea Rodríguez-CorreaPaula Andrea Rodríguez-Correa
Paula Andrea Rodríguez-Correa
JPJuan Camilo Patiño-Vanegas
Juan Camilo Patiño-Vanegas
MBMartha Benjumea-Arias
Martha Benjumea-Arias
Jhony De La Cruz VargasJhony De La Cruz Vargas
Jhony De La Cruz Vargas
GMGustavo Moreno-López
Gustavo Moreno-López
This study aims to identify the factors associated with the adoption of drone delivery in Medellín, Colombia, in the context of the COVID-19 pandemic. For that purpose, it implemented the Diffusion of Innovation (DOI) theory and the Technology Acceptance Model (TAM), which have constructs that complement each other to determine the decision to accept a given technology. A survey was administered to 121 participants in order to validate the model proposed here, which is based on variables that reflect the perceived attributes and risks of this innovation and individuals’ characteristics. The results indicate that the factors Performance Risk, Compatibility, Personal Innovativeness, and Relative Advantage of Environmental Friendliness have the greatest influence on Intention to Use Drone Delivery (mediated by Attitude Towards Drone Delivery). This paper offers relevant information for the academic community and delivery companies because few other studies have investigated this topic. Additionally, the proposed technology adoption model can be a benchmark for other emerging economies in similar social, economic, and technological conditions.

15 October 2019 in Revista de la Facultad de Medicina Humana
Verified
Journal Article
Open access
PDF file
Jhony De La Cruz VargasJhony De La Cruz Vargas
Jhony De La Cruz Vargas
Today we have the honor and joy of sharing with the scientific and university community that the “Revista de la Facultad de Medicina Humana de la Universidad Ricardo Palma” (Journal of the Faculty of Human Medicine of the Ricardo Palma University) is now indexed on multiple national and international databases, the most recent is in Scielo. All this has been possible thanks to all the support received by the authorities of the University and especially from our Rector Dr. Iván Rodríguez Chávez, who at all times gave us his motivation, support, encouragement and has inspired us with his example and job. The indexing process of a scientific journal is laborious; it requires time and the confluence of skilled human resources, teamwork, identity with the University, institutional policy will to have the technical and administrative elements necessary to achieve the objectives, but especially a research editing team, with leadership and management capacity. Hoy tenemos el honor y la alegría de compartir con la comunidad científica y universitaria que la “Revista de la Facultad de Medicina Humana de la Universidad Ricardo Palma” se encuentra indexada en múltiples bases nacionales e internacionales, la mas reciente en Scielo.Todo esto ha sido posible gracias a todo el apoyo recibido de las autoridades de la Universidad, y especialmente de nuestro Rector el Dr. Iván Rodríguez Chávez, quien en todo momento nos brindó su motivación, respaldo, apoyo y nos ha inspirado con su ejemplo y trabajo.El proceso de indización de una revista científica es laborioso, requiere tiempo y la confluencia de recursos humanos capacitados, trabajo en equipo, identidad con la universidad, voluntad política institucional para disponer de los elementos técnicos y administrativos necesarios para alcanzar los objetivos, pero especialmente un equipo editor investigador, con liderazgo y capacidad de gestión.

11 June 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
Jhony De La Cruz VargasJhony De La Cruz Vargas
Jhony De La Cruz Vargas
HGHenry Leonidas Gomez
Henry Leonidas Gomez
JTJesus E. Talavera
Jesus E. Talavera
CGCristhian Gonzales-Rospigliosi
Cristhian Gonzales-Rospigliosi
ACAriana Alessandra Cordova
Ariana Alessandra Cordova
RPRafael Pichardo-Rodriguez
Rafael Pichardo-Rodriguez
Although cytokines mediate inflammation and inflammation facilitates cancer progression, few studies have evaluated the association between specific cytokines and the prognostic value of breast cancer. Therefore, this study aims to address the following question: What is the prognostic relevance of serum IL-6 and TNF-alpha levels on overall survival and treatment response in women with breast cancer? A systematic review and meta-analysis of cohort studies was conducted. The databases consulted included PubMed/Medline, Web of Science, and EMBASE. A total of 1748 articles were identified, of which 10 were included in the review. A significant association was found between elevated levels of IL-6 and TNF-alpha with poor overall survival and poor treatment response. The meta-analysis showed an HR of 3.74 (95% CI: 1.84–7.6) for elevated IL-6 with high heterogeneity (I2: 61%; p = 0.07) and an HR of 3.13 (95% CI: 1.57–6.23) for TNF-alpha with low heterogeneity (I2: 0%; p = 0.9). The overall response rate was 75% (95% CI: 31–100%; I2: 92%). In conclusion, IL-6 and TNF-alpha emerge as prognostic inflammatory biomarkers in women with breast cancer and are associated with poor survival and poor treatment response. This study highlights the need to establish an international consensus on cutoff points and standardized determination methods to implement these biomarkers in clinical practice.

3 October 2008 in Cancer
Verified
Journal Article
Open access
PDF file
ECEduardo Cazap
Eduardo Cazap
ABAntonio Carlos Buzaid
Antonio Carlos Buzaid
CGCarlos Garbino
Carlos Garbino
Jhony De La Cruz VargasJhony De La Cruz Vargas
Jhony De La Cruz Vargas
FOFrancisco Javier Orlandi
Francisco Javier Orlandi
OOOn Behalf Of The Latin American And Caribbean Society Of Medical Oncology
On Behalf Of The Latin American And Caribbean Society Of Medical Oncology
The incidence of breast cancer in Latin American countries is lower than that in more developed countries, whereas the mortality rate is higher. These differences probably are related to differences in screening strategies and access to treatment. Population‐based data are needed to make informed decisions. A 65‐question telephone survey that included 100 breast cancer experts from 12 Latin American countries was conducted in 2006 as an exploratory analysis of the current state of breast cancer treatment in these regions at both at the country level and at the center level. Greater than 90% of countries had no national law or guideline for mammography screening. The access rate to mammography was 66.3% at the country level and 47% at the center level. Variation in care based on level (country vs center) was indicated for the timing of treatment after diagnosis, timing from initial diagnosis to treatment, and the time from surgery to initial chemotherapy. However, the more sophisticated diagnostic testing for hormone receptors and biomarkers were available at most centers (>80%), and, overall, nearly 80% of patients started treatment within 3 months of diagnosis. Variation in care between breast cancer care at the center level versus the country level indicated a need for national cancer care programs. Alternative data collection strategies for understanding the state of breast cancer control programs in developing countries can help identify areas of improvement. Cancer 2008;113(8 suppl):2359–65. © 2008 American Cancer Society.